NDRM NeuroDerm Ltd.

38.85
+0.00  (0%)
Previous Close 38.85
Open 38.90
Price To book 7.97
Market Cap 1023539691
Shares 26,345,938
Volume 0
Short Ratio 3.47
Av. Daily Volume 629,160

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met key primary and secondary endpoints - March 1, 2017.
ND0612H (Trial 006)
Severe Parkinson's Disease
Phase 3 trial suspended, to be replaced by two PK trials due to be initiated 2H 2017.
ND0612L
Parkinson's Disease